Captor Therapeutics®

Disturbing Cancer Resistance with Targeted Degradation of MCL-1

Michał J. Walczak, CSO

28th October 2021

All images by Piotr Piatek

Legal Notice

This document and the information contained herein (unless otherwise indicated) have been prepared by Captor Therapeutics S.A. (the “Issuer”) solely for informational purposes. For this notice, the presentation that follows shall mean and include the slides that follow, the oral presentation of the slides by the Issuer or any person on behalf of the Issuer, any question-and-answer session that follows the oral presentation, hard copies of this document, and any materials distributed at, or in connection with the presentation (collectively, the “Presentation”). By attending the meeting at which the Presentation is made, or by reading the Presentation, you will be deemed to have (i) agreed to all of the following restrictions and made the following undertakings and (ii) acknowledged that you understand the legal and regulatory sanctions attached to the misuse, disclosure or improper circulation of the Presentation.

The information contained in this Presentation may not be reproduced or redistributed in any way, in whole or in part, to any other person without the prior written consent of the Issuer. This Presentation does not purport to contain all the information that may be required by the recipient to assess the Issuer or its securities. The Issuer prepared this Presentation based on the information which it has and from sources believed to be reliable. To the extent available, the industry, market, and competitive position data contained in this Presentation come from official or third-party sources. There is no guarantee of the accuracy or completeness of such data.

This Presentation contains neither a complete nor a comprehensive financial or commercial analysis of the Issuer, nor does it present its position or prospects in a complete or comprehensive manner. The Issuer has prepared the Presentation with due care, however certain inconsistencies or omissions might have appeared in it. Therefore it is recommended that any person who intends to undertake any investment decision regarding any security issued by the Issuer shall only rely on information released as an official communication (i.e. current/periodic reports) in accordance with the legal and regulatory provisions.

This Presentation may contain certain forward-looking statements, forecasts, estimates, projections, and opinions ("Forward-looking Statements"). By their nature, Forward-looking Statements involve known and unknown risks, uncertainties, assumptions, and other factors because they relate to events and depend on circumstances that will occur in the future whether or not outside the control of the Issuer. No representation is made or will be made that any Forward-looking Statements will be achieved or will prove to be correct. Actual future results and operations could vary materially from the Forward-looking Statements. Similarly, no representation is given that the assumptions disclosed in this Presentation upon which Forward-looking Statements may be based are reasonable. The recipient acknowledges that circumstances may change and the contents of this Presentation may become outdated as a result. The assumptions included herein do not constitute profit forecasts or profit estimates.

No warranties or representations can be made as to the comprehensiveness or reliability of the information contained in this Presentation. Neither the Issuer nor its directors, managers, advisers or representatives of such persons shall bear any liability that might arise in connection with any use of this Presentation. Furthermore, no information contained herein constitutes an obligation or representation of the Issuer, its managers or directors, its shareholders, subsidiary undertakings, advisers or representatives of such persons.
Data contained in this Presentation is valid as of the day of its preparation. Consequently, this Presentation will not be subject to changes, updates or modifications to account for events which might occur after this day.

This Presentation does not constitute or form part of, and should not be construed as, an offer to sell or issue, or the solicitation of an offer to purchase, subscribe to, or acquire the Issuer or the Issuer´s securities, or an inducement to enter into investment activity in any jurisdiction in which such offer, solicitation, inducement or sale would be unlawful before registration, exemption from registration or qualification under the securities laws of such jurisdiction. No part of this Presentation, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. This presentation is not for publication, release, or distribution in any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction nor should it be taken or transmitted into such jurisdiction.

About Captor

A global, highly qualified team:

- Based in Wroclaw (Poland) and Basel (Switzerland)
- Backed by private and non-dilutive public funds as well as funds raised in recent IPO
- Disruptive platform in drug discovery
- Five drug programs in large potential markets
- ~85 FTEs on board, almost half of them are PhD level specialists
- Joint experience from more than 11 leading international universities
- 1,100 m^2 of laboratory space equipped with state-of-the-art equipment

Company Pipeline

#	Indications	Modality	Discovery	Preclinical*	IND Filing	FIH**
CT-01	Hepatocellular carcinoma	MG				2023
CT-02	Autoimmunity Liquid tumors	MG				
CT-03	Liquid & solid tumors	BID				
CT-04	Colorectal cancer	BID				
CT-05	Autoimmunity Solid tumors & other	BID				
Partnered Program						
	Gastrointestinal diseases, e.g. IBD			Partnership with Sosei Heptares		

*Preclinical stage include IND-enabling studies
**First in Human; at least 2 projects expected to enter Phase I by 2023
BID – Bifunctional Degrader; MG – Molecular Glue

Captor Therapeutics®

MCL-1: A BREAKTHROUGH APPROACH TO A HIGH-POTENTIAL ONCOGENE

5

Resistance Mechanisms in Cancer

Intrinsic

Pre-existing, e.g.
- Subpopulation of cancer cells resistant to treatment or
- Mutant proteins irresponsive to drugs' activity

Extrinsic

Acquired, e.g.
- Activation of alternative molecular pathway
- Secondary mutation in protein targets, e.g., BCR-ABL T315I

In a heterogenous cell population, only a minority of cells over-express MCL-1

Clonal selection from MCL-1 overexpressing cells in resistant tumor cells

M. Williams & R. Cook (2014) Oncotarget

Antiapoptotic Proteins Are Important Drug Targets



Imbalance in pro- and antiapoptotic proteins dictates the cancer cell survival

Venetoclax (Abbvie), a BCL-2 inhibitor is approved for the treatment of CLL and AML, with over $1.3B sales in 2020

MCL-1 – as a High Potential Oncology Target





Splicing variants of the human MCL-1 gene

Wang H et al. (2021) J Hematol Oncol

MCL-1 inhibitor compounds in development

Compound	Company	Phase
MIK665	Servier/Novartis	I/II
AZD-5991	AstraZeneca	I
AMG176	Amgen	I
PRT1419	Prelude Therapeutics	I



Papatzimas et al. (2019) J Med. Chem

Challenges in Targeting MCL-1 with Small Molecules

(1) MCL-1 inhibitors induce its accumulation in cells



Cancer cell



MV4-11, 6 hours

(2) Need for tight inhibition

(3) Cardiotoxicity concerns

Biophysical Characterization of MCL-1 degraders

MCL-1 binding in FP assay



In cell CRBN-binding assay



MCL-1 degreders cross plasma membrane in HEK293





Ternary Complex Formation

Proteasome-dependent MCL-1 Degradation



MV4-11, 24 hours

*MG132 – Proteasome inhibitor



CRBN-dependent MCL-1 Degradation





OPM-2, 6 hours

Cell Viability in MCL-1 Sensitive & Insensitive Cell Lines

MV4-11 (MCL-1-sensitive)



ARH77 (MCL-1-insensitive)



CPT-2036 is cytotoxic to MCL-1-dependent cell lines

In Vivo Degradation and Apoptosis Induction



CB.17 SCID mice bearing subcutaneous MV4-11 xenografts; 150 mpk, i.p., single dose at t=0



Potent MCL-1 degradation after single dose of CPT-2036

MCL-1 Degraders Show Reduced Cardiac Toxicity

Viability, 14 days treatement



iCell Cardiomyocytes



iCell Cardiomyocytes

Captor MCL-1 degraders don’t induce accumulation in cardiomyocytes

Summary

- Developed potent MCL-1 bi-functional degraders that induce apoptosis *in vivo* after single dose
- MCL-1 degraders show reduced cardiotoxicity compared to inhibitors
- IND-enabling studies planned for H1 2022

Captor Therapeutics®

Captor Therapeutics S.A
ul. Dunska 11
54-427 Wroclaw, Poland

Captor Therapeutics GmbH
Gewerbestrasse 24
4123 Allschwil, Switzerland

For further information:
info@captortherapeutics.com

LinkedIn

All images by Piotr Piatek

Project is co-financed by the European Regional Development Fund:

Inducing apoptosis with small molecules as therapeutic intervention in multiple severe malignancies (POIR.01.01.01-00-0956/17-01)